Evidence map›Paper›PMID 34404439›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

Complement inhibitor CSMD1 modulates epidermal growth factor receptor oncogenic signaling and sensitizes breast cancer cells to chemotherapy.

Chrysostomi Gialeli, Emre Can Tuysuz, Johan Staaf, Safia Guleed, Veronika Paciorek, Matthias Mörgelin, Konstantinos S Papadakos, Anna M Blom

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Chrysostomi GialeliDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Emre Can TuysuzDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Johan StaafDivision of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, Lund, Sweden.
Safia GuleedDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Veronika PaciorekDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Matthias MörgelinColzyx AB, Lund, Sweden.
Konstantinos S PapadakosDepartment of Translational Medicine, Lund University, Malmö, Sweden.
Anna M BlomDepartment of Translational Medicine, Lund University, Malmö, Sweden. anna.blom@med.lu.se.
Lund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman CUB and Sushi multiple domains 1 (CSMD1) is a large membrane-bound tumor suppressor in breast cancer. The current study aimed to elucidate the molecular mechanism underlying the effect of CSMD1 in highly invasive triple negative breast cancer (TNBC).

methodsWe examined the antitumor action of CSMD1 in three TNBC cell lines overexpressing CSMD1, MDA-MB-231, BT-20 and MDA-MB-486, in vitro using scanning electron microscopy, proteome array, qRT-PCR, immunoblotting, proximity ligation assay, ELISA, co-immunoprecipitation, immunofluorescence, tumorsphere formation assays and flow cytometric analysis. The mRNA expression pattern and clinical relevance of CSMD1 were evaluated in 3520 breast cancers from a modern population-based cohort.

resultsCSMD1-expressing cells had distinct morphology, with reduced deposition of extracellular matrix components. We found altered expression of several cancer-related molecules, as well as diminished expression of signaling receptors including Epidermal Growth Factor Receptor (EGFR), in CSMD1-expressing cells compared to control cells. A direct interaction of CSMD1 and EGFR was identified, with the EGF-EGFR induced signaling cascade impeded in the presence of CSMD1. Accordingly, we detected increased  ubiquitination levels of EGFR upon activation in CSMD1-expressing cells, as well as increased degradation kinetics and chemosensitivity. Accordingly, CSMD1 expression rendered tumorspheres pretreated with gefitinib more sensitive to chemotherapy. In addition, higher mRNA levels of CSMD1 tend to be associated with better outcome of triple negative breast cancer patients treated with chemotherapy.

conclusionsOur results indicate that CSMD1 cross-talks with the EGFR endosomal trafficking cascade in a way that renders highly invasive breast cancer cells sensitive to chemotherapy. Our study unravels one possible underlying molecular mechanism of CSMD1 tumor suppressor function and may provide novel avenues for design of better treatment.

Indexed as

Drug Resistance, NeoplasmSignal TransductionAntineoplastic AgentsCell Line, TumorCells, CulturedEndosomesErbB ReceptorsGene ExpressionHumansMembrane ProteinsPrognosisProtein BindingProtein TransportProteomeProteomicsTumor Suppressor ProteinsAntineoplastic AgentsCSMD1 protein, humanEGFR protein, humanErbB ReceptorsMembrane ProteinsProteomeTumor Suppressor ProteinsBreast cancerChemosensitivityCSMD1EGFR trafficking

Identifiers

PMID34404439
PMCPMC8371905
OpenAlexW3193357418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.